Contract Research
Daedalus can offer the following Research Packages:
1) Introduction to Lysosomal Storage Diseases
2) Emerging Therapies in Lysosomal Storage Diseases
3) Orphan Drug Acquisition Strategies
4) Orphan Disorders Secondary to Hepatitis C Infection
5) Chaperone Therapies
6) Protein Misfolding and Aggregation Disorders
7) Protein Misfolding Disorders and Diseases of Aging
8) Early Support of Academic Rare Disease Drug Development
9) Rare Metabolic Disorders with Perinatal Onset
10) Rare Mitochondrial Disorders and Drugs in Development
11) Rare Neuromuscular Disorders and Drugs in Development
12) Introduction to Rare Endocrine Disorders
13) Rare Hepatic Disorders and Compounds in Development
14) Catecholaminergic Polymorphic Ventricular Tachycardia
15) Immune Modulators with G1S Cell Cycle Inhibition
16) Therapeutic Strategies in Lysosomal Storage Diseases
17) Hematological Cancers Secondary to Hepatitis C Infection
18) Autoimmune Disorders related to Hepatitis C Infection
19) Cirrhosis & Mortality in Successfully Treated Hepatitis C
20) Cancer Risk in Successfully Treated Hepatitis C
21) Generic Drug Firms and Small Molecule Orphan Therapies
22) Emerging Therapies in Solid Organ Transplant
23) Waldenstrom’s Macroglobulinemia with Cold Agglutinin Disease
24) Sustained v. Immediate Release Formulations - More than Convenience
25) Hyper-Activation of the Immune System in Chronic Viral Infection
26) Introduction to Hereditary Angioedema (HAE): Current & Emerging Therapies
27) Drug-Induced Respiratory Depression, Emerging Therapies
28) Complement Inhibition and Orphan Disorders
29) Drug Development Stages and Biopharma Asset Values
30) Orphan Drug Spending Trends Worldwide
31) The Future of Orphan Pricing in Europe and the United States
32) Emerging Liver Fibrosis and Cirrhosis Therapies
33) Reviving Clinical Trial Failures for Orphan Indications
34) Strategies to Optimize Pricing of Generic Drugs Repurposed for Orphan Indications
35) Survey of Orphan Disorders with Commercial Size and Drugs in Development
36) Cortisol Modulation and Orphan Disorder Opportunities
37) Intrapulmonary Benzodiazepines for multiple Orphan Disorders
38) Compounds in Development for Orphan Disorders -- 2013
39) Compounds in Development for Orphan Disorders -- 2014
40) Compounds in Development for Orphan Disorders -- 2015
41) Orphan Disorders of Neurodegeneration
42) Orphan Disorders with a Prominent Seizure Component
43) Emerging Therapies in Multiple Myeloma
44) Hepatitis C and Multiple Myeloma
45) Therapies for Multiple Myeloma patients receiving long-term opioid therapy – a commercial and clinical opportunity
46) Busted Compounds. Inexpensive assets with potential in Orphan Indications